Atazanavir/cobicistat

Atazanavir/cobicistat, sold under the brand name Evotaz, is a fixed-dose combination antiretroviral medication used to treat and prevent HIV/AIDS.^[2][3] It contains atazanavir and cobicistat.^[2][3][4] Atazanavir is an HIV protease inhibitor and cobicistat is an inhibitor of cytochrome P450 (CYP) enzymes of the CYP3A family.^[2]

Atazanavir/cobicistat

Combination of
Atazanavir	HIV protease inhibitor
Cobicistat	Cytochrome P450 (CYP3A) inhibitor
Clinical data
Trade names	Evotaz
AHFS/Drugs.com	Professional Drug Facts
License data	US DailyMed: Atazanavir_and_cobicistat
ATC code	J05AR15 (WHO)
Legal status
Legal status	UK: POM (Prescription only)[1] US: ℞-only[2] EU: Rx-only[3]
Identifiers
CAS Number	2446322-19-4
KEGG	D10753

Atazanavir/cobicistat was approved by the Food and Drug Administration (FDA) for medical use in United States in January 2015.^[5][6] It was authorized for medical use in the European Union in July 2015.^[3]

Medical uses

Atazanavir/cobicistat is indicated for use in combination with other antiretroviral agents for the treatment of HIV‑1 infection in people weighing at least 35 kilograms (77 lb).^[2][3]